Dr Reddy’s CEO On Payer Dynamics, China Commitment And Disruption
Dr Reddy’s CEO tells Scrip in an interview that it isn’t business as usual, in general, in the US, where it is refining its proprietary products strategy to focus on ‘bigger assets’ in the backdrop of the payer environment there. The Indian company is, however, upbeat on plans for China.
You may also be interested in...
Shionogi licenses US commercial rights for OIC drug to BioDelivery and rights in three EU markets to Sandoz. Tessa will test its T-cell therapy with Merck’s Keytruda in cervical cancer.
J.P. Morgan Notebook Day 4: US Generics Steady, UroGen, REGENXBIO, Dr. Reddy's In China, And Investor Sentiment Shifts
Daily round-up of news and notes from the 2019 J.P. Morgan Healthcare Conference in San Francisco: US generics see gains, researcher calls for more tech transfer, and biotech investor sentiment rises as big deals bring optimism – among other items from the last day of this year's JPM.
Dr Reddy’s Laboratories appears to be the among the Indian firms considering increasing its activities in China, enthused by the evolving regulatory environment and consequent market opportunities there. The Indian company believes a large basket of products could meet China’s new norms.